Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

NCT04428151 PHASE2 COMPLETED Results posted

Researchers are looking for new ways to treat people with head and neck cancer whose cancer has come back after treatment (recurrent) or whose cancer has spread to other parts of the body (metastatic). Some people with recurrent or metastatic head and neck cancer are treated with chemotherapy and immunotherapy, but the cancer gets worse. The goal of this study is to learn if more people who receive lenvatinib and pembrolizumab have a better overall survival rate than people who receive standard chemotherapy treatment.

Details

Lead sponsor	Merck Sharp & Dohme LLC
Phase	PHASE2
Status	COMPLETED
Enrolment	408
Start date	Thu Aug 06 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Oct 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Squamous Cell Carcinoma of Head and Neck

Interventions

• Lenvatinib
• Pembrolizumab
• Docetaxel
• Capecitabine
• Paclitaxel
• Cetuximab
• Lenvatinib

Countries

Denmark, Colombia, France, Taiwan, United Kingdom, Israel, Norway, South Korea, Romania, Canada, Australia, Portugal, Spain, United States, Brazil